Advertisement
Intensive treatment nearly doubles the risk of severe hypoglycemia requiring medical attention in clinically complex patients

Severe Hypoglycemia Risk Nearly Doubles With Intensive T2DM Tx

0
Findings for clinically complex patients with type 2 diabetes
Romosozumab treatment followed by alendronate is linked to reduced risk of fractures versus alendronate alone for postmenopausal women with osteoporosis

ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis

0
Reduced risk of new vertebral fractures, nonvertebral fractures for romosozumab and alendronate
Genetic variants have been identified in psoriasis patients that correlate with anti-tumor necrosis factor-α treatment response

Genetic Variants ID Treatment Response in Psoriasis

0
Ten SNPs presented that correlate with treatment responses to anti-TNF-α agents

UNAIDS Warns HIV Infections Could Skyrocket Without U.S. Funding

0
By India Edwards HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- The head of the United Nations AIDS agency (UNAIDS) is warning that a...
The overall vaccine effectiveness against any influenza virus associated with medically attended acute respiratory illness is 45 percent for the current influenza season

Vaccine Effectiveness 45 Percent for Flu Virus Linked to ARI

0
Estimated VE 50 percent against influenza B/Victoria viruses, 37 percent against influenza A(H1N1)pdm009

AE Risk Examined for Abiraterone, Enzalutamide in Prostate Cancer

0

Risk for metabolic or cardiovascular adverse events increased for men receiving abiraterone or enzalutamide for advanced disease

Opioid Use in Early Pregnancy Not Tied to Most Birth Defects

0

Second study shows no association for use of macrolides during pregnancy with increase in major birth defects

In patients with myalgic encephalomyelitis/chronic fatigue syndrome

No Benefit Seen With Rituximab for Chronic Fatigue Syndrome

0
B-cell depletion using several rituximab infusions over 12 months not linked to clinical improvement
The National Institutes of Health announced Saturday that a clinical trial evaluating hydroxychloroquine for the treatment of COVID-19 has been stopped because the drug likely provides no benefit.

NIH Stops Hydroxychloroquine Trial

0
Although there was no harm, data and safety monitoring board found the drug 'very unlikely to be beneficial'
Insulin infusion helps achieve glycemic targets and may reduce the risk for poor outcomes in patients with hyperglycemia and COVID-19

Improving Glycemic Control May Also Aid COVID-19 Outcomes

0
Insulin infusion may reduce risk for severe disease in those with hyperglycemia and COVID-19